Physician profile
Dorothea E Spambalg
NPI 1568406809
$3,549.84
in general payments reported to CMS, 2019-2025
14 companies · $437 in 2025
The $437 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.35 · 2020: $240 · 2021: $275 · 2022: $505 · 2023: $1,099 · 2024: $916 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,419 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,419.17 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $981.97 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $853.52 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Alexion Pharmaceuticals, INC. | $700.59 | 2021-2025 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $354.85 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $149.38 | 2023-2024 | Gvoke Hypopen |
| Medtronic, INC. | $101.56 | 2022-2025 | Minimed 780g |
| Ibsa Pharma INC. | $83.00 | 2020-2023 | Tirosint, Licart |
| Insulet Corporation | $79.91 | 2022-2025 | Omnipod |
| Radius Health, INC. | $68.69 | 2023-2024 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.96 | 2023-2024 | Jardiance |
| Mannkind Corporation | $52.57 | 2020 | |
| Amgen INC. | $28.84 | 2019 | |
| Corcept Therapeutics | $20.49 | 2025 | Korlym |
| Tandem Diabetes Care, INC. | $18.51 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorothea Spambalg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.